CORRECTION Open Access



Correction to: Integrated analysis of microRNA regulatory network in nasopharyngeal carcinoma with deep sequencing

Fan Wang¹, Juan Lu¹, Xiaohong Peng¹, Jie Wang¹, Xiong Liu¹, Xiaomei Chen¹, Yiqi Jiang³, Xiangping Li^{1*} and Bao Zhang^{2*}

Correction to: J Exp Clin Cancer Res 35, 17 (2016) https://doi.org/10.1186/s13046-016-0292-4

Following publication of the original article [1], the authors identified a minor error in Fig. 4; specifically:

• Fig. 4b: The authors discovered that they had copied the results of different exposure times of the actin corresponding to CCDN1 to the actin assay corresponding to the CDK6 protein. The correct blot is now used to show the actin assay corresponding to the CDK6 protein.

The corrected figure is given here. The correction does not have any effect on the final conclusions of the paper.

Author details

¹Department of Otolaryngology, Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. ²School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou 510515, China. ³Department of Guangdong No.2 District, BGI Genomics Co.,Ltd, Shenzhen 518083, China.

The original article can be found online at https://doi.org/10.1186/s13046-016-0292-4.

Full list of author information is available at the end of the article

Published online: 08 March 2022

Reference

 Wang F, Lu J, Peng X, et al. Integrated analysis of microRNA regulatory network in nasopharyngeal carcinoma with deep sequencing. J Exp Clin Cancer Res. 2016;35:17. https://doi.org/10.1186/s13046-016-0292-4.



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/loublicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data

^{*}Correspondence: li321162@qq.com; zhang20051005@126.com

¹ Department of Otolaryngology, Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

² School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou 510515, China

Wang et al. J Exp Clin Cancer Res (2022) 41:84 Page 2 of 2




Fig. 4 MiR-34c levels during NPC progression and target genes validation. **a** The expression level of miR-34c-5p in human NPC specimens compared with control biopsy samples. **b** miR-34c-5p expression was higher in stage I, whereas stages II-IV had lower levels. **c** The protein expression levels of MET, CCND1, CDK6 and BCL2 in miR-34c mimic transfected CNE-2 cells were lower than the controls. Western blot was independently repeated at least three times. MicroRNA abundance was normalised to U6 RNA. Statistical analysis was performed using the t-tests (**a, c**) and the one-way ANOVA (**b**)